AMG 511

AMG 511 is a potent and selective small molecule inhibitor of class I phosphoinositide 3-kinases (PI3K), developed by Amgen for the treatment of various cancers. It functions as a pan-PI3K inhibitor, targeting the alpha, beta, delta, and gamma isoforms of the catalytic subunit. By binding to the ATP-binding pocket of these enzymes, AMG 511 blocks the phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-trisphosphate (PIP3), thereby inhibiting the downstream activation of the AKT signaling pathway. In preclinical studies, AMG 511 demonstrated significant anti-tumor activity in human tumor xenograft models harboring PI3K pathway mutations or PTEN loss, including glioblastoma, colorectal, and breast cancer models. The drug's mechanism of action involves the inhibition of tumor cell and endothelial cell proliferation, as well as the induction of tumor cell apoptosis.